医学
血压
心脏病学
心力衰竭
内科学
气压感受器
肾脏疾病
冠状动脉疾病
疾病
重症监护医学
颈动脉
高血压的病理生理学
舒张期
抗高血压药
颈总动脉
肾
自主神经系统
糖尿病
病理生理学
交感神经系统
临床试验
原发性高血压
颈动脉疾病
肾动脉
抵抗性高血压
压力反射
颈动脉体
作者
Min Zhang,Peng Li,Yanhui Sheng
摘要
The World Health Organization (WHO) estimates that the number of people living with hypertension (blood pressure (BP) of ≥ 140 mmHg systolic or ≥ 90 mmHg diastolic or on medication) doubled between 1990 and 2019, from 650 million to 1.28 billion. Elevated BP is associated with increased risks of stroke, coronary artery disease (CAD), heart failure (HF), and chronic kidney disease (CKD). Resistant hypertension (RH) is defined as office BP ≥ 140/90 mmHg despite treatment with three classes of antihypertensive agents (including a diuretic) at maximally tolerated doses, or the need for four or more agents regardless of BP level. Device-based antihypertensive therapies primarily target autonomic nervous system through techniques, such as renal denervation, carotid baroreceptor activation, and carotid body ablation. This review outlines the pathophysiological basis of selected interventions, critically evaluates existing clinical evidence, and highlights future directions for their development and integration into clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI